1
|
Danlos FX, Grajeda-Iglesias C, Durand S, Sauvat A, Roumier M, Cantin D, Colomba E, Rohmer J, Pommeret F, Baciarello G, Willekens C, Vasse M, Griscelli F, Fahrner JE, Goubet AG, Dubuisson A, Derosa L, Nirmalathasan N, Bredel D, Mouraud S, Pradon C, Stoclin A, Rozenberg F, Duchemin J, Jourdi G, Ellouze S, Levavasseur F, Albigès L, Soria JC, Barlesi F, Solary E, André F, Pène F, Ackerman F, Mouthon L, Zitvogel L, Marabelle A, Michot JM, Fontenay M, Kroemer G. Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death Dis 2024; 15:142. [PMID: 38355585 PMCID: PMC10866964 DOI: 10.1038/s41419-024-06519-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2024]
Affiliation(s)
- François-Xavier Danlos
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Claudia Grajeda-Iglesias
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- INSERM U1138, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Sylvère Durand
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Allan Sauvat
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Mathilde Roumier
- Service de Médecine Interne, Hôpital Foch, 92150, Suresnes, France
| | - Delphine Cantin
- Service d'Accueil des Urgences, AP-HP, Hôpital Hôtel-Dieu, 75004, Paris, France
| | - Emeline Colomba
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Julien Rohmer
- Service de Médecine Interne, Hôpital Foch, 92150, Suresnes, France
| | - Fanny Pommeret
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Giulia Baciarello
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Christophe Willekens
- Département d'Hématologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Marc Vasse
- Service de biologie clinique, Hôpital Foch, 92150, Suresnes, France
| | - Frank Griscelli
- Service de virologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Jean-Eudes Fahrner
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Anne-Gaëlle Goubet
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Agathe Dubuisson
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Lisa Derosa
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, 94800, Villejuif, France
| | | | - Delphine Bredel
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Séverine Mouraud
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Caroline Pradon
- Département de Biologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Annabelle Stoclin
- Département de Réanimation, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Flore Rozenberg
- Service de Virologie, AP-HP. Centre-Université de Paris, Hôpital Cochin, Paris, France
| | - Jérôme Duchemin
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
| | - Georges Jourdi
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
- Université de Paris, Innovative Therapies in Haemostasis, INSERM 1140, F-75006, Paris, France
| | - Syrine Ellouze
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
| | - Françoise Levavasseur
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
| | - Laurence Albigès
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | | | - Fabrice Barlesi
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France
| | - Eric Solary
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Département d'Hématologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- INSERM U1287, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Fabrice André
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- INSERM U981, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Frédéric Pène
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
- Service de Médecine Intensive et Réanimation, AP-HP, Hôpital Cochin, 75014, Paris, France
| | - Félix Ackerman
- Service de Médecine Interne, Hôpital Foch, 92150, Suresnes, France
| | - Luc Mouthon
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
- Service de Médecine Interne, AP-HP, Hôpital Cochin, 75014, Paris, France
| | - Laurence Zitvogel
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, 94800, Villejuif, France
| | - Aurélien Marabelle
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, 94800, Villejuif, France
- Département d'Innovation Thérapeutique et des Essais Précoces, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Jean-Marie Michot
- Département d'Hématologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Département d'Innovation Thérapeutique et des Essais Précoces, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Michaela Fontenay
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
| | - Guido Kroemer
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France.
- Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France.
- Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, 75015, Paris, France.
- Suzhou Institute for Systems Biology, Chinese Academy of Sciences, Suzhou, China.
- Department of Women's and Children's Health, Karolinska University Hospital, 17176, Stockholm, Sweden.
| |
Collapse
|
2
|
Benchoufi M, Bokobza J, Chauvin A, Dion E, Baranne ML, Levan F, Gautier M, Cantin D, d'Humières T, Gil-Jardiné C, Benenati S, Orbelin M, Martinez M, Pierre-Kahn N, Diallo A, Vicaut E, Bourrier P. Comparison Between Lung Ultrasonography Score in the Emergency Department and Clinical Outcomes of Patients With or With Suspected COVID-19: An Observational Multicentric Study. J Ultrasound Med 2023; 42:2883-2895. [PMID: 37688781 DOI: 10.1002/jum.16329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Revised: 07/24/2023] [Accepted: 08/23/2023] [Indexed: 09/11/2023]
Abstract
OBJECTIVE Chest CT is the reference test for assessing pulmonary injury in suspected or diagnosed COVID-19 with signs of clinical severity. This study aimed to evaluate the association of a lung ultrasonography score and unfavorable clinical evolution at 28 days. METHODS The eChoVid is a multicentric study based on routinely collected data that was conducted in 8 emergency units in France; patients were included between March 19, 2020 and April 28, 2020 and underwent lung ultrasonography, a short clinical assessment by 2 emergency physicians blinded to each other's assessment, and chest CT. Lung ultrasonography consisted of scoring lesions from 0 to 3 in 8 chest zones, thus defining a global score (GS) of severity from 0 to 24. The primary outcome was the association of lung damage severity as assessed by the GS at day 0 and patient status at 28 days. Secondary outcomes were comparing the performance between GS and CT scan and the performance between a new trainee physician and an ultrasonography expert in scores. RESULTS For the 328 patients analyzed, the GS showed good performance in predicting clinical worsening at 28 days (area under the receiver operating characteristic curve [AUC] 0.83, sensitivity 84.2%, specificity 76.4%). The GS showed good performance in predicting the CT severity assessment (AUC 0.84, sensitivity 77.2%, specificity 83.7%). CONCLUSION A lung ultrasonography GS is a simple tool that can be used in the emergency department to predict unfavorable assessment at 28 days in patients with COVID-19.
Collapse
Affiliation(s)
- Mehdi Benchoufi
- Center for Clinical Epidemiology, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
- METHODS Team, Center for Research in Epidemiology and Statistics Sorbonne Paris Cité (CRESS-UMR 1153), Paris, France
- PICUS, Point of Care UltraSound Institute, Paris, France
| | - Jerôme Bokobza
- PICUS, Point of Care UltraSound Institute, Paris, France
- Adult Emergency Department, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Anthony Chauvin
- Adult Emergency Department, Hôpital Lariboisière, Inserm U942 MASCOT, Université de Paris, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Elisabeth Dion
- Imaging Department Hôtel Dieu, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France
- Centre de Recherche de l'Inflammation (CRI), INSERM U1149, Paris, France
| | - Marie-Laure Baranne
- Center for Clinical Epidemiology, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
- PICUS, Point of Care UltraSound Institute, Paris, France
| | - Fabien Levan
- Adult Emergency Department, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Maxime Gautier
- PICUS, Point of Care UltraSound Institute, Paris, France
- Adult Emergency Department, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Delphine Cantin
- Imaging Department Hôtel Dieu, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France
| | - Thomas d'Humières
- Physiology Department, Henri Mondor University Hospital, Créteil, France
| | - Cédric Gil-Jardiné
- Adult Emergency Department SAMU-SMUR, Pellegrin Hospital, University Hospital Center, Bordeaux, France
- Bordeaux Population Health, INSERM U1219, IETO Team, Bordeaux University, Bordeaux, France
| | - Sylvain Benenati
- Adult Emergency Department, Hospital Group South Ile-de-France, Melun, France
| | - Mathieu Orbelin
- Adult Emergency Department, New Civil Hospital, Strasbourg, France
| | - Mikaël Martinez
- Adult Emergency Department, Forez Hospital Center, Montbrison, France
- Nord Emergency Network Ligérien Ardèche (REULIAN), Hospital Center Le Corbusier, Firminy, France
| | - Nathalie Pierre-Kahn
- Imaging Department Hôtel Dieu, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France
| | - Abdourahmane Diallo
- Clinical Trial Unit Hospital, Lariboisière St-Louis AP-HP, Paris University, Paris, France
| | - Eric Vicaut
- Clinical Trial Unit Hospital, Lariboisière St-Louis AP-HP, Paris University, Paris, France
| | - Pierre Bourrier
- Imaging Department Saint-Louis Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France
| |
Collapse
|
3
|
Chavarot N, Melenotte C, Amrouche L, Rouzaud C, Sberro-Soussan R, Pavie J, Martinez F, Pouvaret A, Leruez-Ville M, Cantin D, Fourgeaud J, Delage C, Vimpere D, Peraldi MN, Legendre C, Lanternier F, Zuber J, Scemla A, Anglicheau D. Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection. Kidney Int 2022; 101:1290-1293. [PMID: 35421508 PMCID: PMC9001009 DOI: 10.1016/j.kint.2022.04.003] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Revised: 03/16/2022] [Accepted: 04/05/2022] [Indexed: 02/05/2023]
Affiliation(s)
- Nathalie Chavarot
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
| | - Clea Melenotte
- Université de Paris, Paris, France; Department of infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Lucile Amrouche
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Claire Rouzaud
- Université de Paris, Paris, France; Department of infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Rebecca Sberro-Soussan
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Juliette Pavie
- Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, Paris, France
| | - Frank Martinez
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Anne Pouvaret
- Université de Paris, Paris, France; Department of infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Marianne Leruez-Ville
- Université de Paris, Paris, France; Virology Laboratory, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Delphine Cantin
- COVID-19 screening center, Emergency Department, Hôtel Dieu Hospital, Assistance Publique-Hôpitaux de Paris, France
| | - Jacques Fourgeaud
- Université de Paris, Paris, France; Virology Laboratory, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Claire Delage
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Damien Vimpere
- Adult Intensive Care Unit, Department of Anaesthesiology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Marie Noëlle Peraldi
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Christophe Legendre
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Fanny Lanternier
- Université de Paris, Paris, France; Department of infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Julien Zuber
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Anne Scemla
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Dany Anglicheau
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| |
Collapse
|
4
|
Danlos FX, Grajeda-Iglesias C, Durand S, Sauvat A, Roumier M, Cantin D, Colomba E, Rohmer J, Pommeret F, Baciarello G, Willekens C, Vasse M, Griscelli F, Fahrner JE, Goubet AG, Dubuisson A, Derosa L, Nirmalathasan N, Bredel D, Mouraud S, Pradon C, Stoclin A, Rozenberg F, Duchemin J, Jourdi G, Ellouze S, Levavasseur F, Albigès L, Soria JC, Barlesi F, Solary E, André F, Pène F, Ackerman F, Mouthon L, Zitvogel L, Marabelle A, Michot JM, Fontenay M, Kroemer G. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death Dis 2021; 12:258. [PMID: 33707411 PMCID: PMC7948172 DOI: 10.1038/s41419-021-03540-y] [Citation(s) in RCA: 87] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Revised: 02/09/2021] [Accepted: 02/10/2021] [Indexed: 02/07/2023]
Abstract
The circulating metabolome provides a snapshot of the physiological state of the organism responding to pathogenic challenges. Here we report alterations in the plasma metabolome reflecting the clinical presentation of COVID-19 patients with mild (ambulatory) diseases, moderate disease (radiologically confirmed pneumonitis, hospitalization and oxygen therapy), and critical disease (in intensive care). This analysis revealed major disease- and stage-associated shifts in the metabolome, meaning that at least 77 metabolites including amino acids, lipids, polyamines and sugars, as well as their derivatives, were altered in critical COVID-19 patient's plasma as compared to mild COVID-19 patients. Among a uniformly moderate cohort of patients who received tocilizumab, only 10 metabolites were different among individuals with a favorable evolution as compared to those who required transfer into the intensive care unit. The elevation of one single metabolite, anthranilic acid, had a poor prognostic value, correlating with the maintenance of high interleukin-10 and -18 levels. Given that products of the kynurenine pathway including anthranilic acid have immunosuppressive properties, we speculate on the therapeutic utility to inhibit the rate-limiting enzymes of this pathway including indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase.
Collapse
Affiliation(s)
- François-Xavier Danlos
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Claudia Grajeda-Iglesias
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- INSERM U1138, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Sylvère Durand
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Allan Sauvat
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Mathilde Roumier
- Service de Médecine Interne, Hôpital Foch, 92150, Suresnes, France
| | - Delphine Cantin
- Service d'Accueil des Urgences, AP-HP, Hôpital Hôtel-Dieu, 75004, Paris, France
| | - Emeline Colomba
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Julien Rohmer
- Service de Médecine Interne, Hôpital Foch, 92150, Suresnes, France
| | - Fanny Pommeret
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Giulia Baciarello
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Christophe Willekens
- Département d'Hématologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Marc Vasse
- Service de biologie clinique, Hôpital Foch, 92150, Suresnes, France
| | - Frank Griscelli
- Service de virologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Jean-Eudes Fahrner
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Anne-Gaëlle Goubet
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Agathe Dubuisson
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Lisa Derosa
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, 94800, Villejuif, France
| | | | - Delphine Bredel
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Séverine Mouraud
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Caroline Pradon
- Département de Biologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Annabelle Stoclin
- Département de Réanimation, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Flore Rozenberg
- Service de Virologie, AP-HP. Centre-Université de Paris, Hôpital Cochin, Paris, France
| | - Jérôme Duchemin
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
| | - Georges Jourdi
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
- Université de Paris, Innovative Therapies in Haemostasis, INSERM 1140, F-75006, Paris, France
| | - Syrine Ellouze
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
| | - Françoise Levavasseur
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
| | - Laurence Albigès
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | | | - Fabrice Barlesi
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France
| | - Eric Solary
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Département d'Hématologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- INSERM U1287, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Fabrice André
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- INSERM U981, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Frédéric Pène
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
- Service de Médecine Intensive et Réanimation, AP-HP, Hôpital Cochin, 75014, Paris, France
| | - Félix Ackerman
- Service de Médecine Interne, Hôpital Foch, 92150, Suresnes, France
| | - Luc Mouthon
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
- Service de Médecine Interne, AP-HP, Hôpital Cochin, 75014, Paris, France
| | - Laurence Zitvogel
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, 94800, Villejuif, France
| | - Aurélien Marabelle
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, 94800, Villejuif, France
- Département d'Innovation Thérapeutique et des Essais Précoces, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Jean-Marie Michot
- Département d'Hématologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Département d'Innovation Thérapeutique et des Essais Précoces, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Michaela Fontenay
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
| | - Guido Kroemer
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France.
- Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France.
- Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, 75015, Paris, France.
- Suzhou Institute for Systems Biology, Chinese Academy of Sciences, Suzhou, China.
- Department of Women's and Children's Health, Karolinska University Hospital, 17176, Stockholm, Sweden.
| |
Collapse
|
5
|
Bayle C, Cantin D, Vidal JS, Sourdeau E, Slama L, Dumesges N, Trombert S, Ayllon S, Nguyen JM, Slama D, Medaghecha M, Hanon O, Salmon D. Asymptomatic SARS COV-2 carriers among nursing home staff: A source of contamination for residents? Infect Dis Now 2021; 51:197-200. [PMID: 33521774 PMCID: PMC7834689 DOI: 10.1016/j.idnow.2020.11.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Revised: 11/06/2020] [Accepted: 11/13/2020] [Indexed: 12/21/2022]
Abstract
Objectives To show that circulation of SARS-COV-2 in nursing homes in France can come from staff as well as residents’ families, whether they are known or not to have had COVID-19. Methods This study reports a screening campaign of asymptomatic staff working in elderly nursing homes in Paris where the virus had been circulating actively in March and April 2020. Results Before the screening campaign, the rate of symptomatic COVID-19 was 23.3% among the residents and 12.1% among their home employees. Within a 72 h screening period, all employees not known to have the virus were screened by RT-PCR in nasopharyngeal swabs. Among the 241 screened employees, 32 (13.3%) tested positive for SARS-CoV-2 on RT-PCR. SARS-CoV-2 carriers and non-carriers did not differ in term of gender, age or type of staff. Staff carrying SARS-CoV-2 were strictly asymptomatic in 75% of cases while during the days following or before the test, 25% presented mild symptoms of COVID-19. Considering both symptomatic and asymptomatic cases, 66 out of 281 (23.5%) of the home employees had been carriers for COVID-19. Conclusion Screening for viral carriage of asymptomatic staff in nursing homes can avoid contact and transmission to frequently severely vulnerable residents.
Collapse
Affiliation(s)
- Catherine Bayle
- Geriatry Department, Broca Hospital, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Paris, France.,EA 4468, Université Paris Descartes, Paris, France
| | - Delphine Cantin
- COVID-19 screening center, Emergency Department, Hotel Dieu Hospital, Assistance Publique-Hôpitaux de Paris, 75004 Paris, France
| | - Jean-Sebastien Vidal
- Geriatry Department, Broca Hospital, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Paris, France.,EA 4468, Université Paris Descartes, Paris, France
| | - Elise Sourdeau
- COVID-19 screening center, Emergency Department, Hotel Dieu Hospital, Assistance Publique-Hôpitaux de Paris, 75004 Paris, France
| | - Laurence Slama
- COVID-19 screening center, Emergency Department, Hotel Dieu Hospital, Assistance Publique-Hôpitaux de Paris, 75004 Paris, France.,Infectious Diseases and Immunology Unit, Hotel Dieu Hospital, 1, place du Parvis de Notre-Dame, 75004 Paris, France
| | - Nicolas Dumesges
- COVID-19 screening center, Emergency Department, Hotel Dieu Hospital, Assistance Publique-Hôpitaux de Paris, 75004 Paris, France
| | | | - Sonia Ayllon
- Emergency Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, 75004 Paris, France
| | - Jean-Marie Nguyen
- Geriatry Department, Broca Hospital, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Paris, France
| | - Dorsaf Slama
- Infectious Diseases and Immunology Unit, Hotel Dieu Hospital, 1, place du Parvis de Notre-Dame, 75004 Paris, France
| | - Mohamed Medaghecha
- Infectious Diseases and Immunology Unit, Hotel Dieu Hospital, 1, place du Parvis de Notre-Dame, 75004 Paris, France
| | - Olivier Hanon
- Geriatry Department, Broca Hospital, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Paris, France.,EA 4468, Université Paris Descartes, Paris, France
| | - Dominique Salmon
- COVID-19 screening center, Emergency Department, Hotel Dieu Hospital, Assistance Publique-Hôpitaux de Paris, 75004 Paris, France.,Infectious Diseases and Immunology Unit, Hotel Dieu Hospital, 1, place du Parvis de Notre-Dame, 75004 Paris, France.,University of Paris, School of Medicine, 75005, Paris, France
| | | |
Collapse
|
6
|
Dumesges N, Slama L, Sourdeau E, Cantin D, Salmon D. Personnel asymptomatique pour le SARS-COV-2 en EHPAD : une source de contamination des résidents ? Med Mal Infect 2020. [PMCID: PMC7441856 DOI: 10.1016/j.medmal.2020.06.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Introduction Matériels et méthodes Résultats Conclusion
Collapse
|
7
|
Slama D, Bartier S, Hautefort C, Bequignon E, Etienne N, Pietri M, Sourdeau E, Cantin D, Corre A, Salmon D. L’anosmie : critère spécifique de l’atteinte COVID-19 « Coranosmie1 ». Med Mal Infect 2020. [PMCID: PMC7442127 DOI: 10.1016/j.medmal.2020.06.155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Introduction Depuis le mois d’avril, les publications médicales suggèrent que l’anosmie est un symptôme fréquent lors d’une infection liée au COVID-19. Notre objectif était de déterminer la valeur prédictive positive (VVP) et la spécificité (Sp) de l’anosmie et de décrire sa prévalence et ses caractéristiques chez les patients COVID-19. Matériels et méthodes Il s’agissait d’une étude prospective observationnelle longitudinale d’une cohorte multicentrique des patients consultants entre le 17 et le 24 mars 2020, pour anosmie depuis moins de 9 jours sans autres signes typiques d’infection à COVID-19. Les patients considérés comme COVID-19 positifs sont ceux ayant eu une RT-PCR COVID-19 positive sur les sécrétions nasopharyngées, ou ayant un contact documenté avec un patient COVID-19 positif. Sur 1824 patients, nous avons comparé la performance diagnostique de l’anosmie par rapport à celle des patients présentant une toux ou des céphalées. Comme pour l’anosmie, nous n’avons incus dans cette comparaison que les patients présentant des symptômes depuis moins de 9 jours. Résultats Parmi les 55 patients ayant consulté pour anosmie, 51 (IC92,7 % [82,4–97,9]) avait une RT-PCR positive. La charge virale était modérée pour les 51 patients avec un taux médian de CT à 28,83 (27,55–32,72). L’âge moyen des 55 patients était 35,7 ± 9,7 ans ; 56,4 % étaient des femmes. Dix-neuf patients (34,5 %) avaient des antécédents de rhinite allergique et 12 (21,8 %) étaient des fumeurs actifs. Aucun patient avait des antécédents de trouble de l’olfaction chronique. Une anosmie totale a été rapportée pour 47/55 patients (85,5 %) et une hyposmie pour 8 patients (14,5 %). L’anosmie était d’installation brutale dans 88,7 % des cas (n = 47/55) et associée à une dysgueusie dans 80 % des cas (n = 44/55). Une obstruction nasale était retrouvée chez seulement 2 patients. Les autres symptômes les plus fréquemment retrouvés étaient les céphalées (n = 37, 68,5 %), l’asthénie (n = 28, 57,1 %) et la toux (n = 22, 40,7 %). L’anosmie était inaugurale chez 16 patients (29,1 %). Pour les autres patients, elle a commencé 3 (2–4) jours après le début de l’infection. Aucun de nos patients a eu une évolution vers une forme grave. À j15, la majorité des patients (72,9 %) ont partiellement récupéré l’odorat. L’analyse effectuée sur 1824 avait démontré que la VVP (77,8 % [73,8–81,6]) de l’anosmie et sa Sp (90,2 %, [88,2–92,0]) étaient plus élevées que celles de la toux (VVP : 47,3 % [45,0–49,5], Sp : 34,3 % [32,2–36,4]) ou les céphalées (VVP : 47,9 % [45,7–50,1], Sp : 36,7 % [34,5–38,8]). Conclusion L’anosmie paraît un symptôme spécifique et a une VVP élevée par rapport aux autres symptômes classiques de l’infection COVID. Elle est dans la majorité des cas d’installation brutale, sans obstruction nasale, souvent associée à une dysgueusie, et d’évolution a priori favorable.
Collapse
|
8
|
Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L, Almire C, Hénon C, Kosmider O, Droin N, Rameau P, Catelain C, Alfaro A, Dussiau C, Friedrich C, Sourdeau E, Marin N, Szwebel TA, Cantin D, Mouthon L, Borderie D, Deloger M, Bredel D, Mouraud S, Drubay D, Andrieu M, Lhonneur AS, Saada V, Stoclin A, Willekens C, Pommeret F, Griscelli F, Ng LG, Zhang Z, Bost P, Amit I, Barlesi F, Marabelle A, Pène F, Gachot B, André F, Zitvogel L, Ginhoux F, Fontenay M, Solary E. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Cell 2020; 182:1401-1418.e18. [PMID: 32810439 PMCID: PMC7405878 DOI: 10.1016/j.cell.2020.08.002] [Citation(s) in RCA: 552] [Impact Index Per Article: 138.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 06/12/2020] [Accepted: 07/31/2020] [Indexed: 12/18/2022]
Abstract
Blood myeloid cells are known to be dysregulated in coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2. It is unknown whether the innate myeloid response differs with disease severity and whether markers of innate immunity discriminate high-risk patients. Thus, we performed high-dimensional flow cytometry and single-cell RNA sequencing of COVID-19 patient peripheral blood cells and detected disappearance of non-classical CD14LowCD16High monocytes, accumulation of HLA-DRLow classical monocytes (Human Leukocyte Antigen - DR isotype), and release of massive amounts of calprotectin (S100A8/S100A9) in severe cases. Immature CD10LowCD101−CXCR4+/− neutrophils with an immunosuppressive profile accumulated in the blood and lungs, suggesting emergency myelopoiesis. Finally, we show that calprotectin plasma level and a routine flow cytometry assay detecting decreased frequencies of non-classical monocytes could discriminate patients who develop a severe form of COVID-19, suggesting a predictive value that deserves prospective evaluation.
Collapse
Affiliation(s)
- Aymeric Silvin
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Nicolas Chapuis
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France
| | - Garett Dunsmore
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | | | - Agathe Dubuisson
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Lisa Derosa
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France; Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Carole Almire
- Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France
| | - Clémence Hénon
- INSERM U981, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Olivier Kosmider
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France
| | - Nathalie Droin
- INSERM U1287, Gustave Roussy Cancer Campus, Villejuif 94800, France; INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Philippe Rameau
- INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Cyril Catelain
- INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Alexia Alfaro
- INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Charles Dussiau
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France
| | - Chloé Friedrich
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France
| | - Elise Sourdeau
- Service des Urgences, AP-HP, Hôpital Hôtel-Dieu, Paris 75014, France
| | - Nathalie Marin
- Service de Médecine Intensive et Réanimation, AP-HP, Hôpital Cochin, Paris 75014, France
| | - Tali-Anne Szwebel
- Service de Médecine Interne, AP-HP, Hôpital Cochin, Paris 75014, France
| | - Delphine Cantin
- Service des Urgences, AP-HP, Hôpital Hôtel-Dieu, Paris 75014, France
| | - Luc Mouthon
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service de Médecine Interne, AP-HP, Hôpital Cochin, Paris 75014, France
| | - Didier Borderie
- Service de Diagnostic Biologique Automatisé, AP-HP, Hôpital Cochin, Paris 75014, France
| | - Marc Deloger
- INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Delphine Bredel
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Severine Mouraud
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Damien Drubay
- INSERM U1018, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Muriel Andrieu
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France
| | | | - Véronique Saada
- Département de Biologie et Pathologie, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Annabelle Stoclin
- Service de Réanimation Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Christophe Willekens
- INSERM U1287, Gustave Roussy Cancer Campus, Villejuif 94800, France; Département d'Hématologie, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Fanny Pommeret
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Frank Griscelli
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France; Département de Biologie et Pathologie, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Lai Guan Ng
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos Building #3-4, Biopolis, Singapore 138648, Singapore
| | - Zheng Zhang
- Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong Province, China
| | - Pierre Bost
- Systems Biology Group, Department of Computational Biology and USR 3756, Institut Pasteur and CNRS, Paris 75015, France; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
| | - Ido Amit
- Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
| | - Fabrice Barlesi
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Aurélien Marabelle
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Frédéric Pène
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service de Médecine Intensive et Réanimation, AP-HP, Hôpital Cochin, Paris 75014, France
| | - Bertrand Gachot
- Service de Réanimation Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France
| | - Fabrice André
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France; INSERM U981, Gustave Roussy Cancer Campus, Villejuif 94800, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France
| | - Laurence Zitvogel
- INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France; Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, Villejuif 94800, France
| | - Florent Ginhoux
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos Building #3-4, Biopolis, Singapore 138648, Singapore; Shanghai Institute of Immunology, Shanghai JiaoTong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, China; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore 169856, Singapore.
| | - Michaela Fontenay
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France.
| | - Eric Solary
- INSERM U1287, Gustave Roussy Cancer Campus, Villejuif 94800, France; Service de Réanimation Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France.
| |
Collapse
|
9
|
Salmon Ceron D, Bartier S, Hautefort C, Nguyen Y, Nevoux J, Hamel AL, Camhi Y, Canouï-Poitrine F, Verillaud B, Slama D, Haim-Boukobza S, Sourdeau E, Cantin D, Corré A, Bryn A, Etienne N, Rozenberg F, Layese R, Papon JF, Bequignon E. Self-reported loss of smell without nasal obstruction to identify COVID-19. The multicenter Coranosmia cohort study. J Infect 2020; 81:614-620. [PMID: 32650110 PMCID: PMC7338860 DOI: 10.1016/j.jinf.2020.07.005] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Revised: 07/02/2020] [Accepted: 07/03/2020] [Indexed: 12/23/2022]
Abstract
Isolated loss of smell without nasal obstruction is an early red-flag of COVID-19. These patients should adopt all the preventive measures and a lockdown. Olfactory/gustative dysfunction had high predictive value to identify COVID-19. Olfactory/gustative dysfunction had high specificity to identify COVID-19. Self-reported loss of smell, among other symptoms, could help to screen COVID-19.
Objectives To determine the frequency of SARS-CoV-2 positive samples in a subset of patients consulting for primarily isolated acute (<7 days) loss of smell and to assess the diagnostic accuracy of olfactory/gustatory dysfunction for COVID-19 diagnosis in the overall population tested for COVID-19 in the same period. Methods Prospective multicentric cohort study in four olfactory ENT units and a screening center for COVID-19. Results i) Among a subset of 55 patients consulting for primarily recent loss of smell, we found that 51 (92.7%) had a COVID-19 positive test (median viral load of 28.8 cycle threshold). Loss of smell was mostly total (anosmia), rarely associated with nasal obstruction but associated with a taste disorder in 80%. Olfactory dysfunction occurred suddenly, either as first complaint or preceded by mild symptoms occurring a median of 3 days. The majority of patients (72.9%) partially recovered the sense of smell within 15 days. ii) In a population of 1824 patients tested for COVID-19, the positive predictive value and the specificity of loss of smell and/or taste were 78.5% and 90.3% respectively (sensitivity (40.8%), negative predictive value (63.6%)). Conclusions Self-reported loss of smell had a high predictive positive value to identify COVID-19. Making this sign well known publicly could help to adopt isolation measures and inform potential contacts.
Collapse
Affiliation(s)
- Dominique Salmon Ceron
- Department of Infectious Diseases and Immunology, Hotel Dieu Hospital, Paris Public Hospitals (APHP), 1 Place du Parvis de Notre-Dame, Paris 75004, France; University of Paris, School of Medicine, Paris 75005, France.
| | - Sophie Bartier
- Department of Oto-rhino-laryngology, Head and Neck Surgery, Intercommunal Hospital of Créteil, Créteil 94000, France; University Paris-Est Créteil (UPEC), School of Medicine, Créteil 94000, France; INSERM U955, IMRB- CEpiA team, 94000 Créteil, France Paris Public Hospitals Henri Mondor Hospital (APHP), Créteil 94000, France; Department of Oto-rhino-laryngology, Henri Mondor Hospital of Créteil, Paris Public Hospitals, Créteil 94000, France; Centre National de la Recherche Scientifique CNRS, ERL 7000, Créteil 94000, France
| | - Charlotte Hautefort
- Department of Oto-rhino-laryngology Head and Neck Surgery, Paris Public Hospitals, Lariboisière Hospital (APHP), Paris 75010, France; University Paris Diderot, School of Medicine, Paris 75010, France
| | - Yann Nguyen
- Department of Oto-rhino-laryngology Head and Neck Surgery, Paris Public Hospitals, AP-HP Sorbonne University Hospital Pitié Salpêtrière Hospital (AP-HP), Paris 75006, France; Sorbonne University, Paris 75013, France
| | - Jérôme Nevoux
- Groupe Hospitalier Paris-Saclay, Hôpital Bicêtre, Department of Oto-rhino-laryngology Head and Neck Surgery, Paris Public Hospitals. Le Kremlin-Bicêtre 94270, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre F-94275, France
| | - Anne-Laure Hamel
- Department of Oto-rhino-laryngology Head and Neck Surgery, Paris Public Hospitals, Lariboisière Hospital (APHP), Paris 75010, France; University Paris Diderot, School of Medicine, Paris 75010, France
| | - Yohan Camhi
- Department of Oto-rhino-laryngology Head and Neck Surgery, Paris Public Hospitals, AP-HP Sorbonne University Hospital Pitié Salpêtrière Hospital (AP-HP), Paris 75006, France
| | - Florence Canouï-Poitrine
- University Paris-Est Créteil (UPEC), School of Medicine, Créteil 94000, France; INSERM U955, IMRB- CEpiA team, 94000 Créteil, France Paris Public Hospitals Henri Mondor Hospital (APHP), Créteil 94000, France; Clinical Research Unit: (URC-Mondor), Department of Public Health, Henri Mondor Hospital Paris Public Hospitals (AP-HP), Créteil 94000, France
| | - Benjamin Verillaud
- Department of Oto-rhino-laryngology Head and Neck Surgery, Paris Public Hospitals, Lariboisière Hospital (APHP), Paris 75010, France; University Paris Diderot, School of Medicine, Paris 75010, France
| | - Dorsaf Slama
- Department of Infectious Diseases and Immunology, Hotel Dieu Hospital, Paris Public Hospitals (APHP), 1 Place du Parvis de Notre-Dame, Paris 75004, France
| | | | - Elise Sourdeau
- Emergency Department, Hotel Dieu Hospital, Paris Public Hospitals (APHP), Paris 75004, France
| | - Delphine Cantin
- Emergency Department, Hotel Dieu Hospital, Paris Public Hospitals (APHP), Paris 75004, France
| | - Alain Corré
- Department of Oto-rhino-laryngology Head and Neck Surgery, Hopital Rothschild Foundation, Paris, France
| | - Agnes Bryn
- University of Paris, School of Medicine, Paris 75005, France; General Medical Practioner, Paris, France
| | - Nicolas Etienne
- Department of Infectious Diseases and Immunology, Hotel Dieu Hospital, Paris Public Hospitals (APHP), 1 Place du Parvis de Notre-Dame, Paris 75004, France
| | - Flore Rozenberg
- University of Paris, School of Medicine, Paris 75005, France; Virology Department, Cochin Hospital, Paris Public Hospitals (APHP), Paris 75004, France
| | - Richard Layese
- University Paris-Est Créteil (UPEC), School of Medicine, Créteil 94000, France; INSERM U955, IMRB- CEpiA team, 94000 Créteil, France Paris Public Hospitals Henri Mondor Hospital (APHP), Créteil 94000, France; Clinical Research Unit: (URC-Mondor), Department of Public Health, Henri Mondor Hospital Paris Public Hospitals (AP-HP), Créteil 94000, France
| | - Jean-François Papon
- INSERM U955, IMRB- CEpiA team, 94000 Créteil, France Paris Public Hospitals Henri Mondor Hospital (APHP), Créteil 94000, France; Centre National de la Recherche Scientifique CNRS, ERL 7000, Créteil 94000, France; Groupe Hospitalier Paris-Saclay, Hôpital Bicêtre, Department of Oto-rhino-laryngology Head and Neck Surgery, Paris Public Hospitals. Le Kremlin-Bicêtre 94270, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre F-94275, France
| | - Emilie Bequignon
- Department of Oto-rhino-laryngology, Head and Neck Surgery, Intercommunal Hospital of Créteil, Créteil 94000, France; University Paris-Est Créteil (UPEC), School of Medicine, Créteil 94000, France; INSERM U955, IMRB- CEpiA team, 94000 Créteil, France Paris Public Hospitals Henri Mondor Hospital (APHP), Créteil 94000, France; Department of Oto-rhino-laryngology, Henri Mondor Hospital of Créteil, Paris Public Hospitals, Créteil 94000, France; Centre National de la Recherche Scientifique CNRS, ERL 7000, Créteil 94000, France
| | | |
Collapse
|
10
|
Freund R, Krivine A, Prévost V, Cantin D, Aslangul E, Avril MF, Claessens YE, Rozenberg F, Casetta A, Baixench MT, Dumaine V, Launay O, Loulergue P. Measles immunity and measles vaccine acceptance among healthcare workers in Paris, France. J Hosp Infect 2013; 84:38-43. [PMID: 23433868 DOI: 10.1016/j.jhin.2013.01.002] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2012] [Accepted: 01/10/2013] [Indexed: 11/27/2022]
Abstract
BACKGROUND In Europe, including France, a measles outbreak has been ongoing since 2008. Unprotected healthcare workers (HCWs) may contract and spread the infection to patients. AIM The objective of this study was to evaluate HCWs' measles immunity and vaccine acceptance in our setting. METHODS In a survey-based study conducted in three university hospitals in Paris, 351 HCWs were included between April and June 2011. The following data were collected at enrolment: age, hospital unit, occupation, history of measles infection and vaccination, previous measles serology and acceptance of a measles vaccination in case of seronegativity. Sera were tested for the presence of specific anti-measles IgG antibodies using the CAPTIA(®) measles enzyme-linked immunosorbent assay. FINDINGS The mean age of the participating HCWs was 36 years (range: 18-67) and 278 (79.2%) were female. In all, 104 four persons (29.6%) declared a history of measles, and 90 (25.6%) declared never having received a measles vaccination. Among the 351 HCWs included in the study, 322 (91.7%) were immunized against measles (IgG >90 mIU/mL). The risk factors for not being protected were age [18-29 years, adjusted odds ratio: 2.7 (95% confidence interval: 1.1-6.9) compared with ≥30 years], no history of measles infection or vaccination. The global acceptance rate for a measles vaccination, before knowing their results, was 78.6%. CONCLUSION In this cohort of HCWs, 8.3% were susceptible to measles; the group most represented were aged <30 years. Acceptance of the measles vaccine was high. A vaccination campaign in healthcare settings should target specifically healthcare students and junior HCWs.
Collapse
Affiliation(s)
- R Freund
- Université Paris-Descartes, INSERM, CIC BT505, Assistance Publique-Hôpitaux de Paris, CIC de Vaccinologie Cochin Pasteur, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Cantin D, Marks R. Corticosteroid Injections and the Treatment of Achilles Tendonitis: A Narrative Review. Res Sports Med 2011. [DOI: 10.1080/0308355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Yordanov Y, Cantin D, Le Guerroué G, Pourriat JL. [Metal fume fever, an almost forgotten disease]. Ann Fr Anesth Reanim 2010; 29:395-396. [PMID: 20378299 DOI: 10.1016/j.annfar.2010.03.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/08/2009] [Accepted: 03/09/2010] [Indexed: 05/29/2023]
Abstract
Metal fume fever is an ancient and almost forgotten occupational disease found among welders. Diagnosis is made difficult by the frequency and the non-specific flue-like symptomatology. We present the cases of three patients admitted for developing the symptoms after being exposed to welding fumes. Treatment was symptom based. Severe cases have been described after exposure to military fumes.
Collapse
Affiliation(s)
- Y Yordanov
- Service des urgences, hôtel Dieu, faculté de médecine Paris-Descartes, université Paris-5, AP-HP, 1, place du Parvis-Notre-Dame, 75004 Paris, France
| | | | | | | |
Collapse
|
13
|
Benoit T, Bowes C, Bowman N, Cantin D, Chudley A, Crolly D, Livingston A, Longstaffe S, Marles S, Miller C, Millar M, Penko M, Prasad C, Riguidel J, Wincott L. Telemedicine diagnosis for fetal alcohol syndrome - The Manitoba experience. Paediatr Child Health 2002; 7:147-51. [PMID: 20046287 PMCID: PMC2794808 DOI: 10.1093/pch/7.3.147] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The diagnosis of fetal alcohol syndrome has been possible, with increasing precision, since the original descriptions in the 1970s. Multidisciplinary diagnostic approaches have been recognized as most appropriate, although they are often not available. Telemedicine has been used in Canada over the same time period for a variety of diagnositc applications.Since 1999, funding by the Manitoba government has allowed the consolidation of services for children with prenatal alcohol exposure in Manitoba, and has allowed the development of a format for diagnosis using telemedicine.This paper describes the authors' experience with the above and offers observations that may be helpful to other programs that are focused on developing this format for the diagnosis of fetal alcohol syndrome.
Collapse
Affiliation(s)
- T Benoit
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba
| | - C Bowes
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba
| | - N Bowman
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba
| | - D Cantin
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba
| | - A Chudley
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba
| | - D Crolly
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba
| | - A Livingston
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba
| | - S Longstaffe
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba
| | - S Marles
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba
| | - C Miller
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba
| | - M Millar
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba
| | - M Penko
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba
| | - C Prasad
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba
| | - J Riguidel
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba
| | - L Wincott
- Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba
| |
Collapse
|
14
|
Abstract
Numerical calculations using the Prony method have shown that the feedback coefficient in unstable laser resonators can be increased by factors of as much as 5 over the geometrical value using a mirror with a phase step at its center. A phase shift of close to pi over an area of an equivalent Fresnel number of 0.5 leads to minimum output losses. Experiments with a TEA CO(2) laser confirm the prediction. The results can be attributed to a cancellation of the output wave by destructive interference, which confines the laser beam around the resonator axis.
Collapse
|
15
|
Affiliation(s)
- D Cantin
- Laboratoire de Chimie Analytique, U.F.R. de Pharmacie, Université J. Fourier de Grenoble, La Tronche, France
| | | | | |
Collapse
|
16
|
Abstract
Pure orellanine extracted from the mushroom Cortinarius orellanus is highly toxic in mice both when given intraperitoneally (LD50 = 12.5 mg/kg) or per os (LD50 = 90 mg/kg). The kidneys of mice injected i.p. with orellanine show similar tubular necrosis to that obtained with whole mushroom given per os. This demonstrates that orellanine is the true, principal toxin of C. orellanus. The similarity of the structures of the toxin and of bipyridinium herbicides such as methylviologen (paraquat) or the nephrotoxic diquat led other authors to presume a similar mechanism for orellanine toxicity. Our study of the electrochemical behaviour of orellanine shows that its mechanism of action has to be different from that of these poisons.
Collapse
Affiliation(s)
- J M Richard
- Laboratoire de Chimie et Toxicologie, U.F.R. de Pharmacie, Université J. Fourier, Grenoble, France
| | | | | |
Collapse
|
17
|
Abstract
Orellanine, a toxic principle of Cortinarius orellanus Fr., efficiently inhibited the photosynthetic activity of duckweed, Lemna minor L., at a concentration of 0.4 mM. A lower concentration (0.06 mM) blocked the O2 production in isolated spinach class A chloroplasts. However, no effect was observed on thylakoids (class C chloroplasts), showing that orellanine does not interfere with the chloroplastic electron transfer chain and that orellanine does not act like methylviologen (paraquat) in green plants, as previously suggested. An electrochemical study of orellanine and related compounds showed that orellanine can neither be reduced by electrons derived from H2O nor from NADPH, as is methylviologen in plant and animal cells, respectively.
Collapse
|
18
|
Sirianni L, Cantin D, Latulippe N. [The cosmetics industry]. Infirm Can 1980; 22:25. [PMID: 6904376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
19
|
Roche Y, Cantin D, Vigier J, Boucherle A. [Qualitative and quantitative determination of amino-2 benzimidazole in aqueous medium by polarography (author's transl)]. Toxicol Eur Res 1978; 1:109-12. [PMID: 33469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Amino-2 Benzimidazole, a residue of the decomposition of some fungicides (Benomyl, Carbendazine, Thiophanate, Methylthiophanate), is measured by polarography in aqueous medium, with a platinium rotating electrode, for the exploration in potentials from +0.5 v to 1.4 v. The best conditions for the quantitative determination are investigated, the study according to pH is performed and the standard curve is given for concentrations from 10(-5) to 10(-3) M/l. The interaction of elementts found in tap water and in aquarium water is also investigated.
Collapse
|
20
|
Cantin D, Alary J, Coeur A. [Progesterone and synthetic progestens in pharmaceutical forms (use of differential pulse polarography) (author's transl)]. J Pharm Belg 1977; 32:255-63. [PMID: 894483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
21
|
Coeur A, Cantin D, Alary J. [Determination of adrenaline in the presence of a primary aromatic amine (an injectable solution of procaine hydrochloride and adrenaline)]. Ann Pharm Fr 1972; 30:801-7. [PMID: 4668285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|